Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)

Inclusion Criteria:

• Patient was diagnosed with probable MSA-C (cerebellar) or MSA-P (parkinsonian)variant within 60 months of symptom onset (excluding impotence)

• Subject can ambulate without the assistance of another person, defined as theability to take at least 10 steps. Use of assistive devices is allowed

• Patient cognitive state permits him to sign informed consent, according to the PI'sclinical judgement, and MoCA >= 24

Exclusion Criteria:

• Pregnant women and women before menopause

• Participants with a clinically significant or unstable medical or surgical conditionthat, in the opinion of the investigator, might preclude safe completion of thetreatment or affect the treatment outcome.

• Patients with thrombocytopenia, other bleeding diathesis or taking anticoagulanttherapy (not including Aspirin up to 100mg per day)

• Patients with known hypersensitivities to Plasmalyte, Gadolinium, Penicillin, andwith general hypersensitivity to antibiotics

• Patients who fulfill the criteria of Parkinson's Disease

• History of electroconvulsive therapy

• History of brain surgery